Gut microbiota in AML patients during chemotherapy (Belgium)
20 longitudinal gut microbiome samples from Belgium, from patients with acute myeloid leukemia (other cancer) sampled across induction chemotherapy (at diagnosis, end of chemo, and discharge). machine-written summary
20 samples · 20 runs · BE · Age unknown · 2023 · 19.93 Gbp / sample
One study deposited as 2 BioProjects (80 catalog samples together): PRJNA813705 · PRJNA875377 · show together
Checked this project's papers and archive records yourself? Mark it human-verified.
what each source gave
| ✓ Sequence archive | 160 sample values (collection date, country, health condition, health condition detail, latitude, location region, longitude, subject id) |
| – Abstract / description | no abstract or project description |
| – Full text | no open-access full text linked |
| – Supplementary tables | no supplementary tables available (or none open access) |
| – External resources | not covered by the external resources we ingest |
| – User contribution | nothing uploaded yet |
| – Human verified | not yet checked by a person · I checked this project — verify it |
intervention — arms not resolved
Other administered intervention (see intervention_detail) design observational_with_procedure · population other_cancer · Gut microbiota sampled at diagnosis, end of induction chemo, and discharge; AML patients
“at diagnostic, at the end of the chemo and at discharge” — bioproject.description (study level; per-sample arms are in the intervention column below)
longitudinal
10 of 10 people sampled more than once (20 samples; median 2, up to 2 per person) · follow-up median 17 d (max 23 d) · median interval between samples 17 d (time from collection dates). Schedule stated by the source: “Samples collected before any therapeutic intervention (T0), at end of induction chemotherapy (T1), and at discharge (T4)”.
Each row is one person (10 shown); dots are samples at days since that person's first sample.
Genera, mean relative abundance over 17 profiled gut samples of this project (Sandpiper SingleM profiles, GTDB R232; low-depth and non-metagenome profiles left out).
| field | samples | coverage | R1 | R2 | R3 | R4 |
|---|---|---|---|---|---|---|
| age_category | 0 | 0% | ||||
| country | 20 | 100% | 20 | |||
| health_condition | 20 | 100% | 20 | |||
| subject_id | 20 | 100% | 20 | |||
| collection_date | 20 | 100% | 20 | |||
| detailed_location | 20 | 100% | ||||
| health_condition_detail | 20 | 100% | 20 | |||
| latitude | 20 | 100% | 20 | |||
| location_region | 20 | 100% | 20 | |||
| longitude | 20 | 100% | 20 |
- Gut microbiota alterations induced by intensive chemotherapy in acute myeloid leukaemia patients are associated with gut barrier dysfunction and body weight loss. 2023 PMID 37806074 own_data
Archive description
Evaluation of gut microbiota composition and functional potential in patients with acute myeloid leukemia over the time of the induction chemotherapy (at diagnostic, at the end of the chemo and at discharge). MicroAML clinical study. Study design available on ClinicalTrials.gov (NCT03881826). Data published and discussed in Potgens, Lecop et al, Clinical Nutrition 2023. 16S and metagenomics raw data are shared.
How this project entered the registry
Classified as human gut / stool shotgun DNA metagenome of age unknown by sonnet_x2 with confidence 0.62. Assay shotgun_dna.
- host study.title · “patients with acute myeloid leukemia”
- body site study.title · “gut microbiota composition”
Evidence examples (one per field × route)
| sample | field | value | route | conf. | source | quote |
|---|---|---|---|---|---|---|
| SAMN30615016 | collection_date | 2017-10-31 | R1 | 0.90 | biosample.attribute:collection_date | 2017-10-31 |
| SAMN30615016 | country | BE | R1 | 0.90 | sample.attr.geo_loc_name | Belgium |
| SAMN30615016 | health_condition | other_cancer | R1 | 0.85 | biosample_attr | AML |
| SAMN30615016 | health_condition_detail | AML | R1 | 0.90 | sample.attr.host_disease | AML |
| SAMN30615016 | latitude | 50.8500 | R1 | 0.90 | biosample.attribute:lat_lon | 50.85 N 4.46 E |
| SAMN30615016 | location_region | Flanders | R1 | 0.60 | biosample.attribute:lat_lon | 50.85 N 4.46 E |
| SAMN30615016 | longitude | 4.4600 | R1 | 0.90 | biosample.attribute:lat_lon | 50.85 N 4.46 E |
| SAMN30615016 | subject_id | 105 | R1 | 0.70 | sample.name_rule:alias | 105T1 |
Sequencing
20 runs over 20 samples · mean 20.76 Gbp per run (median 19.93 Gbp, total 415.20 Gbp; 20 runs with a base count) · layout PAIRED 20 · platform ILLUMINA 20 · models Illumina NovaSeq 6000 (20) · 85% of runs with a Sandpiper profile · first public 2023-11-10
Authors (0)
No author record.
Downloads
PRJNA875377.csv.gz (1.5 KB) · parquet (70.7 KB) — all 20 samples, every field with route and confidence · PRJNA875377_determinations.csv.gz (1.8 KB) — 160 evidence rows